# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

> **NCT07179653** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Grand Theravac Life Sciences (Nanjing) Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- HBV Infection

## Interventions

- **DRUG:** TVAX-008
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07179653
- **Lead sponsor:** Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179653, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07179653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*